Minimally important differences and risk levels for the Composite Asthma Severity Index-Reference-Cited by-同舟云学术

Minimally important differences and risk levels for the Composite Asthma Severity Index

Published:2017-03 Issue:3 Volume:139 Page:1052-1055
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Krouse Rebecca Z.,Sorkness Christine A.,Wildfire Jeremy J.,Calatroni Agustin,Gruchalla Rebecca^ORCID,Hershey Gurjit K. Khurana,Kattan Meyer,Liu Andrew H.,Makhija Melanie,Teach Stephen J.,West Joseph B.,Wood Robert A.,Zoratti Edward M.,Gergen Peter J.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference8 articles.

1. Development and validation of the Composite Asthma Severity Index–an outcome measure for use in children and adolescents;Wildfire;J Allergy Clin Immunol,2012

2. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children;Busse;N Engl J Med,2011

3. Minimal clinically important difference: defining what really matters to patients;McGlothlin;JAMA,2014

4. The minimally important difference of the Asthma Control Test;Schatz;J Allergy Clin Immunol,2009

5. Pathways through which asthma risk factors contribute to asthma severity in inner-city children;Liu;J Allergy Clin Immunol,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omics in nasal epithelium reveals three axes of dysregulation for asthma risk in the African Diaspora populations;Nature Communications;2024-05-28

2. The Child Opportunity Index 2.0 and exacerbation‐prone asthma in a cohort of urban children;Pediatric Pulmonology;2024-04

3. Definitions of non-response and response to biological therapy for severe asthma: a systematic review;ERJ Open Research;2023-01-26

4. Life Course of Asthma;Precision Approaches to Heterogeneity in Asthma;2023

5. AIM2ACT: Randomized controlled trial protocol for a mobile health intervention for early adolescents with asthma;Contemporary Clinical Trials;2022-12